Morning Overview on MSN
The FDA cleared a breast cancer drug that added five months of survival for hard-to-treat tumors
Women diagnosed with advanced triple-negative breast cancer who cannot receive immunotherapy now have a new first-line ...
Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...
AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.
The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader ...
Hearing the words "triple-negative breast cancer" (TNBC) can be overwhelming. It's a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...
A preclinical study by researchers at Baylor College of Medicine has uncovered a mechanism that allows triple-negative breast cancer (TNBC) to develop resistance to immune checkpoint blockade (ICB) ...
Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...
Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results